Clinical study on anti-infective reconstituted bone xenograft for treatmeat of chronic hematogenous osteomyelitis / 中国矫形外科杂志

ABSTRACT

[Objective] To study the effect of anti-infective reconstituted bone xenograft(ARBX)on treating chronic hematogenous osteomyelitis as one-stage grafting.[Method]ARBX was used to treat 24 cases of chronic hematogenous osteomyelitis as one-stage grafting after debridement since September of 2001,17 cases of which were followed up for an average period of 34 months(range,12 to 79 months).[Result]Except 1 case failed to cure,and 1 resulted in recurrence of infection,and 1 with large segmental bone defect nonunion post-operatively,other 14 cases were cured,the cure rate was 82.4% which was better than traditional therapy.[Conclusion]ARBX has high osteoinductive activity and enhanced anti-infective capability,which enables it to be used as primary grafting to treat chronic hematogenous osteomyelitis.